Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Farnebo, Jacob ^a   Grybäck, Per ^a   Harmenberg, Ulrika ^a   Laurell, Anna ^b   Wersäll, Peter ^a   Blomqvist, Lennart K ^a   Ullén, Anders ^a   Sandström, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarker; FDG PET; Renal cell carcinoma; Targeted therapy; Total lesion glycolysis

Indexed keywords

ALPHA INTERFERON; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; PAZOPANIB; SORAFENIB; SUNITINIB; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATIONAL STUDY; DRUG RESPONSE; DRUG UPTAKE; GLYCOLYSIS; HUMAN; KIDNEY METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; SWEDEN; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CONE BEAM COMPUTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; TREATMENT OUTCOME;

AGED; CARCINOMA, RENAL CELL; CONE-BEAM COMPUTED TOMOGRAPHY; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84904724583     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-408     Document Type: Article

References (20)

1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, . TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134. 10.1056/NEJMoa060655, 17215530, TARGET Study Group.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124. 10.1056/NEJMoa065044, 17215529.
3. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28(6):1061-1068. 10.1200/JCO.2009.23.9764, 20100962.
4. van Cruijsen H, van der Veldt A, Hoekman K. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Bioscie 2009, 14:2248-2268.
5. Treglia G, Mirk P, Stefanelli A, Rufini V, Giordano A, Bonomo L. 18 F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. Clin Imaging 2012, 36(3):167-175. 10.1016/j.clinimag.2011.08.012, 22542374.
6. Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, Sano F, Murakami T, Kishida T, Miura T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Inoue T, Kubota Y, Nakaigawa N. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 2012, 12:162. 10.1186/1471-2407-12-162, 3418566, 22551397.
7. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, Powles T. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 2011, 17(18):6021-6028. 10.1158/1078-0432.CCR-10-3309, 21742806.
8. Hatt M, Groheux D, Martineau A, Espie M, Hindie E, Giacchetti S, de Roquancourt A, Visvikis D, Cheze-Le Rest C. Comparison between 18 F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 2013, 54(3):341-349. 10.2967/jnumed.112.108837, 23327900.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
10. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122S-150S. 2755245, 19403881.
11. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27(34):5794-5799. 10.1200/JCO.2008.21.4809, 19826129.
12. Lyrdal D, Boijsen M, Suurkula M, Lundstam S, Stierner U. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 2009, 30(7):519-524. 10.1097/MNM.0b013e32832cc220, 19522059.
13. Vercellino L, Bousquet G, Baillet G, Barre E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindie E, Moretti JL. 18 F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 2009, 24(1):137-144. 10.1089/cbr.2008.0527, 19243256.
14. Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA. Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med 2013, 38(3):175-182. 10.1097/RLU.0b013e318279ffdf, 3578161, 23354032.
15. Vanderhoek M, Perlman SB, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med 2012, 53(1):4-11. 10.2967/jnumed.111.093443, 3308343, 22213818.
16. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005, 106(4):1376-1381. 10.1182/blood-2005-01-0272, 15860666.
17. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals Oncol 2005, 16(7):1160-1168.
18. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004, 25(5):433-438. 10.1097/00006231-200405000-00002, 15100500.
19. Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010, 16(4):1216-1225. 10.1158/1078-0432.CCR-09-2175, 20145174.
20. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35(13):1773-1782. 10.1016/S0959-8049(99)00229-4, 10673991.